Literature DB >> 17065138

Avascular necrosis--an antineoplastic-treatment-related toxicity: the experiences of two institutions.

Małgorzata Sawicka-Zukowska1, Lidia Kajdas, Katarzyna Muszynska-Roslan, Maryna Krawczuk-Rybak, Danuta Sonta-Jakimczyk, Tomasz Szczepanski.   

Abstract

Avascular necrosis (avn) is a complication of treatment for malignancies in children and adolescents. The authors present a two-center retrospective of experiences with avn in children treated for acute lymphoblastic leukaemia or non-Hodgkin lymphoma (8 from 191 patients with newly diagnosed disease in total of 19 sites). The median age at diagnosis was 16.6 years. Avn was observed in 4.1% of the group, higher among males than females (7/1), both during and after therapy. Early diagnosis of the process has enabled 7 patients to avoid surgical intervention. The increased incidence of avn, the multimodal character of symptoms, but unknown late consequences of avn showed that prospective studies of early recognition and proper therapy are needed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17065138     DOI: 10.1080/08880010600909938

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  3 in total

1.  Multimodality treatment of a complex series of parallel pathologies in a 16-year-old male that ultimately leads to bilateral hip arthroplasty surgery: A case report.

Authors:  Emmet Cullen; John Quinlan; Esmond Fogarty; Peter Keogh
Journal:  Int J Surg Case Rep       Date:  2012-05-03

2.  [Cortisone-induced humerus head necrosis in acute myeloid leukemia: cartilage-preserving arthroscopic spongioplasty].

Authors:  A Heid; J Dickschas; V Schoeffl
Journal:  Unfallchirurg       Date:  2013-02       Impact factor: 1.000

3.  Osteonecrosis in adult survivors of childhood cancer: a report from the childhood cancer survivor study.

Authors:  Nina S Kadan-Lottick; Irina Dinu; Karen Wasilewski-Masker; Sue Kaste; Lillian R Meacham; Anita Mahajan; Marilyn Stovall; Yutaka Yasui; Leslie L Robison; Charles A Sklar
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 50.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.